Avalo Therapeutics (AVTX)

• Market cap: $307M
• 1 day: -0.94%
• 5 days: -0.29%
• 1 month: -11.9%
• 3 months: 13.23%
• 6 months: 242.42%
• Year to date: -0.41%
• 1 year: 142.14%
• 5 years: -99.76%
• 10 years: -99.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23